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T
he last decade has seen a shift in the therapeu-
tics of type 2 diabetes from insulin-centric to
more multifarious approaches. Whereas previ-
ously drug treatment was based almost entirely
on increasing insulin action—either by giving drugs to
raise plasma insulin levels or to increase tissue respon-
siveness to insulin—it is now clear that addressing other
processes controlling glucose metabolism is also fruitful.
To wit, drugs that delay gastric emptying or carbohydrate
digestion or promote renal glucose elimination have been
shown to be effective for treating hyperglycemia. Com-
pounds that affect hepatic glucose production directly or
act through the central nervous system to lower blood
glucose are in various phases of development. Moreover,
glucagon, long known to contribute to abnormal glucose
regulation in diabetes (1,2), is now amenable to thera-
peutic manipulation using drugs based on the naturally
occurring hormones islet amyloid polypeptide (IAPP,
also known as amylin) and glucagon-like peptide 1
(GLP-1).
GLP-1 is an essential component of the system regulat-
ing blood glucose and has been the basis for two new
classes of drugs to treat diabetes, GLP-1 receptor (GLP-1r)
agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors
(3,4). GLP-1r activation has a broad reach that affects islet
hormone secretion, gastrointestinal motility, food intake,
and glucose production, all in a manner that lowers blood
glucose (5). While enhanced -cell function is generally
accepted to be central in the glycemic response to GLP-1,
it is noteworthy that plasma levels of insulin and C-peptide
in patients treated with GLP-1r agonists and DPP-4 inhib-
itors are not dramatically increased (6–8). This is due in
part to the overall effect of GLP-1 signaling to lower blood
glucose, reducing the glycemic stimulus to the -cells.
With sophisticated modeling of plasma C-peptide levels,
the insulinotropic effects of GLP-1–based drugs are clear
(6,7), but the subtlety of the effect has raised questions
about other mechanisms for glucose lowering. Thus, there
has been a clear reason to focus on other responses to
GLP-1r signaling.
Suppression of glucagon secretion by GLP-1 was de-
scribed soon after the peptide was discovered and was
demonstrable in cultured cells, animals, and humans.
There remains some question as to whether the effects of
GLP-1 to reduce plasma glucagon in vivo is a direct effect
mediated through GLP-1r on -cells, or whether this effect
is indirect via neural or paracrine mechanisms (3). How-
ever, there is no doubt that some of the most inﬂuential
observations advancing GLP-1 as a model therapeutic
were the demonstrations that intravenous administration
to fasting subjects with diabetes lowered blood glucose
coincident with reductions in plasma glucagon (9,10). This
effect was particularly compelling in a study of type 1
diabetic patients in whom the absence of endogenous
insulin secretion supported reduction of glucagon as the
primary mechanism by which GLP-1 reduced blood glu-
cose (10). Importantly, these effects have been borne out
clinically, since both GLP-1r agonists and DPP-4 inhibitors
reduce plasma glucagon as part of their pharmacologic
activity (11).
In this issue of Diabetes, Hare et al. (12) revisit the
glucagonostatic effects of GLP-1 in the context of fasting
hyperglycemia. The goal of their study was to quantify the
relative contributions of insulin and glucagon to mediate
changes in blood glucose induced by GLP-1. To do this,
they studied a group of middle-aged men with well-
controlled type 2 diabetes who had moderate fasting
hyperglycemia after withdrawal from oral agents. Each
subject had ﬁve separate glucose clamps during which
glycemia was maintained at 10 mmol/l during various
combinations of GLP-1, insulin, glucagon, and somatosta-
tin infusion. In the experiment to deﬁne the GLP-1 effect
(day 1), a supraphysiologic amount of GLP-1 was infused
for 2 h while blood glucose concentrations were held
steady with a variable glucose infusion. Plasma insulin and
glucagon during this treatment reﬂected the actions of
GLP-1 on islet secretion, and the total amount of glucose
required to maintain the clamp was used as the sum of
GLP-1 action. In subsequent experiments (days 2–5), so-
matostatin was given to block the secretion of endogenous
glucagon and insulin, and these peptides were given
intravenously to mimic basal concentrations or levels
obtained during GLP-1 treatment. These treatments were
arranged in speciﬁc combinations to isolate the effects of
GLP-1–stimulated insulin or GLP-1–inhibited glucagon on
glucose requirements during the clamp. The authors re-
port that during the experiments mimicking GLP-1–in-
duced hyperinsulinemia without glucagon suppression
(day 4) and glucagon suppression without elevated plasma
insulin (day 3), the glucose requirements were similar and
half of what was required on day 1 when GLP-1 was given.
When the infusions were adjusted to mimic GLP-1 admin-
istration, i.e., stimulated insulin and suppressed glucagon
together (day 5), the glucose requirements to maintain
stable glycemia were comparable with the GLP-1 infusion
alone. The authors conclude from these ﬁndings that -cell
inhibition and -cell stimulation contribute equally to the
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The ﬁndings of Hare et al. reiterate the important
bihormonal regulation of the islet by GLP-1 and suggest
signiﬁcant beneﬁts from glucagon lowering in the treat-
ment of type 2 diabetes. The general messages of this
paper—that the actions of glucagon contribute to fasting
hyperglycemia in diabetes and that this can be mitigated
by GLP-1—seem beyond question. However, there are
reasons to quibble with the relative effects of -cell
stimulation and -cell inhibition that are estimated from
this study. While logically designed and cleanly executed,
the investigators had to make several assumptions and
compromises in their experiments that potentially affect
the outcomes. The regulation of fasting glucose by insulin
and glucagon occurs primarily through control of hepatic
glucose production and is dependent to a great extent on
concentrations of islet hormones in the hepatic portal vein
(13–15). Because of the substantial clearance of insulin
and glucagon by the liver, steady-state concentrations of
endogenously released islet hormones in the portal vein
are estimated to be 1.5- to 3-fold higher than those in the
peripheral circulation. Mimicking the effects of hepatic
portal insulin and glucagon with exogenous infusions is
difﬁcult in humans because portal venous concentrations
cannot be directly measured, and because the replacement
must be given into a peripheral vein.
Examination of the data presented by Hare et al. sug-
gests that some of the outcomes were biased by difﬁculties
in reproducing portal concentrations of insulin and gluca-
gon to mimic the effects of GLP-1. To recreate the sup-
pressive effects of GLP-1 on portal plasma glucagon, -cell
output was blocked with somatostatin in the absence of
glucagon replacement. Although peripheral glucagon lev-
els during these conditions (days 3 and 5) did not appear
to be very different from those during the GLP-1 infusion
(day 1), portal concentrations of glucagon in these exper-
iments can only be inferred. When GLP-1 was given (day
1), peripheral glucagon levels gradually drifted down from
20 to 5 pmol/l, and it is fair to assume that portal
glucagon was about twice as high. In contrast, on days 3
and 5, peripheral glucagon levels dropped quickly and
approached the limit of detectability, consistent with a
near total inhibition of the -cells. Under these conditions
portal levels would also be minimal, magnifying relative
differences in the amounts of glucagon seen by the liver
with GLP-1 infusion and the experimental reproductions.
Mismatch of portal glucagon during the GLP-1 infusion
and the matching experiments would overestimate the
effects of -cell suppression to lower blood glucose. The
approach to matching plasma insulin during GLP-1 admin-
istration (day 1) and the matching studies (days 4 and 5)
also needs to be considered. Unlike glucagon, insulin has
major effects on peripheral, as well as hepatic, glucose
metabolism. The authors admittedly tried to match periph-
eral insulin levels during their pancreatic clamps so as not
to induce major differences in glucose disposal. However,
this approach does not account for the two- to threefold
greater levels of insulin in portal blood that would be
expected during GLP-1 infusion. As a result, it seems
likely that any effects of GLP-1 to suppress hepatic
glucose production by raising portal levels of insulin
would be missed in the matching experiments, reducing
the apparent insulinotropic impact of GLP-1. The difﬁ-
culty in creating appropriately matched hormonal con-
ditions leaves some doubt as to whether the neat 50–50
split between insulin stimulation and glucagon inhibi-
tion is an accurate depiction of glucose lowering by
GLP-1. Given the considerations discussed above, it seems
likely that insulinotropic effects are quantitatively greater
than glucagonostatic ones. By how much is a question that
requires an experimental paradigm in which portal hormone
levels can be measured and reproduced more precisely.
Unfortunately, we do now have practical ways to do this in
humans.
Do the questions raised about the results in this paper
diminish the importance of the results to the clinical
application of GLP-1 in diabetes? Probably not. The work
of Hare et al. is interesting and informative and, given the
current techniques for studying human subjects, it gives as
close an approximation of GLP-1 effects on islet secretion
as we could ask for. At the least, these results reinforce the
potential of glucagon suppression as a useful adjunct to
the more conventional insulin–action approaches to treat-
ing diabetes. It is probable that the contribution of gluca-
gon to hyperglycemia varies among diabetic patients, and
tailored therapy focused on glucagon lowering might be
especially effective in some individuals. The ability to
target both islet hormones has been one of the novel
additions that GLP-1r agonists and DPP-4 inhibitors bring
to the therapeutic proﬁle for diabetes. GLP-1 has been an
exciting bench-to-bedside success, and taking observa-
tions from the clinical application of GLP-1 back to the lab
for reexamination seems like a fruitful approach for revis-
ing and extending these advances.
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